The number of surgical operations performed globally continues to increase. Although perioperative care has been improved, up to 50% of patients undergoing elective major surgery will experience postoperative complications. The two most common complications are surgical site infection and anastomotic leakage. c complications lead to increased risk of reoperation, prolonged hospital stay, decreased quality of life, higher morbidity and mortality. Therefore, it is very important to optimize the perioperative period of surgical patients to prevent postoperative complications.
One of the main potential causes of postoperative complications is related to surgical stress response. Preventing or reducing the inflammatory stress caused by surgery has been shown to be effective in improving the prognosis of patients. Hyperbaric oxygen therapy (HBOT) can relieve this stress response by giving oxygen intermittently at a pressure higher than the atmospheric pressure at sea level.
The clinically used hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at a pressure exceeding 1.4 atmospheres absolute (ATA). Among them, the established indications of HBOT include radiocystitis or enteritis, osteoradionecrosis, chronic osteomyelitis and chronic wound healing, especially in the case of microangiopathy due to diabetes or radiotherapy. HBOT is also used for preconditioning because it upregulates the defense mechanism against subsequent ischemia.
At the biological level, HBOT improves the formation of new blood vessels and tissue survival after ischemia, promotes the process of bone formation, has antibacterial and bactericidal effects as well as anti-inflammatory effect. HBOT improves the results following reperfusion injury in various organs (such as the brain, liver, muscle, or heart).
Preventive HBOT can also improve tolerance to ischemia in animals, and promote the production of anti-inflammatory proteins and antioxidant enzymes. And a professional hyperbaric chamber supplier can help you with therapy.
The treatment goals of perioperative HBOT include helping wound healing, protecting myocardium and brain, and improving the survival rate of split skin grafts. The number of HBOT hyperbaric treatment for wounds ranges from a minimum of 1 to a maximum of 30.
According to reports, for chest surgery, HBOT can reduce the length of stay in ICU, use of inotropic drugs, advanced angina, intraoperative blood loss and the combination of death, myocardial infarction, coronary artery bypass surgery, and revascularisation of target lesion for thoracic surgery. In plastic surgery, HBOT reduces the need for new surgical procedures, reducing the number of patients with osteoradionecrosis in dental surgery and the number of alveolar sockets where osteoradionecrosis occurs. In plastic surgery, ENT, neurological and urological surgery, HBOT can improve skin graft survival, brain recovery and erectile function/satisfaction. It can also reduce the total epithelialization time of colorectal surgery and the pulmonary complications of general gastrointestinal surgery.
Acceptable conventional indications for HBOT include patients with a history of radiation therapy or diabetes that cause late-stage radiation tissue damage or poor wound healing. These patients respond well to HBOT through neovascularization. Data indicate that perioperative preventive HBOT may be a promising intervening measure to improve the prognosis of surgical patients.